GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

Current and former employees of the CDC are calling for HHS Secretary Robert F. Kennedy Jr.'s resignation after his ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

With U.S. cuts to programs putting millions at risk, Canada needs to provide leadership to help prevent a resurgence of HIV: ...